Strides partners with Kenox to expand nasal spray portfolio for US market
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated